Evonile Pharma Limited has announced a rights issue of 1.02 crore partly paid equity shares at Rs 860 per share to raise Rs 884.75 crore. Existing shareholders as of November 11, 2026, are eligible for the 5:12 ratio offering.
Evonile Pharma Announces Rs 884.75 Crore Rights Issue
Issue Price: Rs 860 per share | Record Date: November 11, 2026
Reader Takeaway: Existing shareholders get a 5:12 entitlement ratio, but must account for two-installment payment structure on these shares.
What just happened
Evonile Pharma Limited has officially announced a rights issue to raise approximately Rs 884.75 crore. The company will offer 1,02,87,832 partly paid equity shares to existing shareholders. The offer price is set at Rs 860 per share, which includes a face value of Rs 5 and a premium of Rs 855. To be eligible, investors must hold the company's shares on the record date of November 11, 2026.
Why this matters
The capital raised will expand the company's equity base, with total outstanding shares projected to reach 34,978,629 if fully subscribed. Investors are required to pay in two installments: Rs 645 per share at the time of application and the remaining Rs 215 as a first and final call. This structure requires shareholders to manage cash flow for the second payment at a future date.
Rights Issue Timeline
- Issue Opens: November 19, 2026
- Market Renunciation: Until November 27, 2026
- Issue Closes: December 03, 2026
- Expected Listing: December 09, 2026
What to track next
Shareholders who do not wish to subscribe to the rights can explore the market renunciation route until November 27, 2026, allowing them to trade their rights entitlements on the exchange. Monitoring the subscription levels after the issue opens on November 19 will be key to gauging market sentiment toward the company's growth plans.